Skip to content

2019 Annual Conference   |   January 30 - February 1, 2019   |   Salt Lake City, Utah, USA

Conference Photos and Videos are NOW ONLINE!  Visit our Conference In Review Page.

January 30 - February 2, 2019
Salt Lake City, Utah

Conference Chairs
Lewis Roberts, MB, ChB, PhD
Lewis Roberts, MB, ChB, PhD
Jennifer Knox, MD, MSc, FRCPC
Jennifer Knox, MD, MSc, FRCPC

2019 Cholangiocarcinoma Foundation Annual Conference

The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by providing a forum to:


Increase knowledge central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma.

A New Perspective

Present a diversity of perspectives focused on basic, translational and clinical research.


Stimulate multi-disciplinary, cross-institutional collaborations.


Foster dialogue
and inspire innovation.

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons
  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies
  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma

Incredible Numbers from our 2018 Conference


from 40 states and 12 countries representing healthcare, industry, patient advocacy organizations, patients, caregivers, academia and supporters.


including those by researchers, surgeons, patients, caregivers and industry specialists.

Medical Institutions

represented, including international key opinion leaders advancing cholangiocarcinoma research, treatment and care.


  • 190 patients/caregivers
  • 29 poster presentations
  • 786 webcast attendees

with support from

  • 30 organizations: ASLAN Pharmaceuticals, Agios, Amsety, ArQule, BTG, Bayer, Boston Scientific, Bristol-Myers Squibb, Conquer Cancer Foundation, doTERRA, Foundation Medicine, H3 Biomedicine, Halozyme, Incyte, Leap Therapeutics, Merck, Mundipharma, Nucana, PCI Biotech, PCORI, Perthera, Promotion in Motion, QED Therapeutics, RedHill Biopharma, Shire, Sirtex, Taiho Oncology, UPMC and Zymeworks.

Don't Wait, Be a Part of our 2019 Conference





Klus Pharma
Shepherd Therapeutics
TriSalus Life Sciences

Funding for this conference was made possible (in part) by a Eugene Washington Engagement Award from the Patient-Centered Outcomes Research Institute (PCORI) allowing 30 patients from around the world to take part in all facets of the conference including speaking, attending sessions, roundtable discussions, and networking events.


Funding for this conference was made possible (in part) by 1R13CA213778-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Scroll To Top